

Chlamydia Screen

©2013 Truven Health Analytics Inc. Proprietary and confidential.

MEASURE DESCRIPTION:

Chlamydia Screen indicates whether a woman, aged 16 to 24 years, had a chlamydia screening test done during the measurement year. This excludes women who had a pregnancy test during the measurement period, followed within 7 days by either a prescription for isotretinoin or an x-ray.

This measure is based on the HEDIS measure *Chlamydia Screening in Women* (CHL).

PROPRIETARY STATUS:

This measure is owned by NCQA [NQF-Endorsed™].

CRITERIA REVISION:

- This measure is based on the HEDIS® 2013 Technical Specifications for Physician Measurement criteria.
- The NDC drug codes used for this measure are from the NCQA files released in November 2012.

CRITERIA REVIEW DATE: 04/01/2013

MEASURE TYPE:

MEASURE PACKAGE: Advantage Nationally Endorsed

MINIMUM DATA REQUIREMENTS (months): 12

MEASURE DETAILS:

DENOMINATOR:

Identifies the unique count of sexually-active women, aged 16 to 24 years at the end of the measurement year. It excludes women who had a pregnancy test during the measurement period, followed within 7 days by either a prescription for isotretinoin or an x-ray.

Contraceptive drugs (during the measurement year)	NDC Codes as defined by NCQA (www.ncqa.org)
OR	
Sexually-active women (during the measurement year)	CPT Procedure Code = 11975-11977, 57022, 57170, 58300, 58301, 58600-58615, 58970-58976, 59000-59899, 76801, 76805, 76811, 76813-76821, 76825-76828, 76941, 76945, 76946, 80055, 81025, 82105, 82106, 82143, 82731, 83632, 83661-83664, 84163, 84702, 84703, 84704, 86592, 86593, 86631, 86632, 87110, 87164, 87166, 87270, 87320, 87490-87492, 87590-87592, 87620-87622, 87660, 87808, 87810, 87850, 88141-88143, 88147-88155, 88164-88167, 88174, 88175, 88235, 88267, 88269 Or HCPCS Procedure Code = G0101, G0123, G0124, G0141, G0143-G0145, G0147, G0148, G0450, H1000, H1001, H1003-H1005, P3000, P3001, Q0091, S0180, S0199, S4981, S8055 Or

	<p>ICD-9 Procedure Code = 69.01, 69.02, 69.51, 69.52, 69.7, 72.0-75.99, 88.78, 97.24, 97.71, 97.73</p> <p>Or</p> <p>ICD-9 Diagnosis Code = 042, 054.10-054.12, 054.19, 078.11, 078.88, 079.4, 079.51-079.53, 079.88, 79.98, 091.0-098.11, 098.15-098.31, 098.35-099.9, 131.00-131.9, 302.76, 339.82, 614.0-615.9, 622.3, 623.4, 625.0, 626.7, 628*, 630-679.14, 795.0*, 795.1*, 796.7*, 996.32, V01.6, V02.7, V02.8, V08, V15.7, V22.0-V26.51, V26.8*, V26.9-V28.9, V45.5*, V61.5-V61.7, V69.2, V72.3*, V72.4*, V73.81, V73.88, V73.98, V74.5, V76.2</p> <p>Or</p> <p>Revenue Code UB = 0112, 0122, 0132, 0142, 0152, 0720-0722, 0724, 0729, 0923, 0925)</p> <p>Or</p> <p>NDC Codes for contraceptives as defined by NCQA (www.ncqa.org)</p>
AND	
Age in years (as of the end of the measurement year)	Age in years = 16-24
And	And
Gender	Gender Code = F

EXCLUSIONS:

Excludes from the eligible population those women who had a pregnancy test during the measurement year, followed within 7 days by either a prescription for isotretinoin or an x-ray.

Pregnancy test (during the measurement year)	<p>(CPT Procedure Code = 81025, 84702, 84703</p> <p>Or</p> <p>Revenue Code UB = 0925)</p>
AND	
X-ray or prescription for isotretinoin (during the 8-day period from the date of the pregnancy test through 7 days following)	<p>(CPT Procedure Code = 70010-76499</p> <p>Or</p> <p>Revenue Code UB = 032*)</p> <p>Or</p> <p>NDC Codes for isotretinoin as defined by NCQA (www.ncqa.org)</p>

NUMERATOR:

Identifies sexually-active women, aged 16 to 24 years, who had a chlamydia screening test done during the measurement year.

At least one chlamydia test (during the measurement year)	CPT Codes = 87110, 87270, 87320, 87490-87492, 87810
---	---

CONTINUOUS ENROLLMENT:

Continuously enrolled with medical coverage during the measurement year, which equates to 12 months out of 12 months.

MEASURE BACKGROUND:

Chlamydia is the most common bacterial sexually-transmitted infection in the United States. An estimated 3 million new cases occur annually, with the majority being asymptomatic when initially infected. Untreated, chlamydia infections can lead to serious complications, including urethritis, cervicitis, pelvic inflammatory disease (PID), infertility, ectopic pregnancy, chronic pelvic pain, and increased risk of human immunodeficiency virus (HIV) infection. Chlamydial infection during pregnancy is related to adverse pregnancy outcomes, including miscarriage, premature rupture of membranes, preterm labor, low birth weight, and infant mortality. Screening women at risk for cervical chlamydia infections is associated with a decrease in these complications.

C. trachomatis is treated with standard antibiotics. However, it often goes untreated, and complications occur despite initial lack of symptoms. Most guidelines indicate that all sexually-active younger women (less than age 24 or 25 years) should be screened, whether or not they are pregnant. The Centers for Disease Control and Prevention (CDC) recommends annual screening for sexually-active nonpregnant women. The U. S. Preventive Services Task Force (USPSTF) recommends against routinely providing screening for chlamydial infection for women aged 25 and older, whether or not they are pregnant, if they are not at increased risk. In addition to sexual activity and age, other risk factors for chlamydial infection include a history of chlamydial or other sexually-transmitted infection, new or multiple sexual partners, and inconsistent condom use.

AMA PCPI Notice of Use. Physician Performance Measures (Measures) and related data specifications, developed by the Physician Consortium for Performance Improvement (the Consortium), are intended to facilitate quality improvement activities by physicians.

These Measures are intended to assist physicians in enhancing quality of care. Measures are designed for use by any physician who manages the care of a patient for a specific condition or for prevention. These performance Measures are not clinical guidelines and do not establish a standard of medical care. The Consortium has not tested its measures for all potential applications. The Consortium encourages the testing and evaluation of its Measures.

Measures are subject to review and may be revised or rescinded at any time by the Consortium. The Measures may not be altered without the prior written approval of the Consortium. Measures developed by the Consortium, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, e.g., use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain. Commercial uses of the Measures require a license agreement between the user and American Medical Association, on behalf of the Consortium. Neither the Consortium nor its members shall be responsible for any use of these Measures.

The Measures are provided as is without warranty of any kind. ©2007 American Medical Association. All Rights Reserved.

CPT® copyright 2012 American Medical Association. All rights reserved. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Applicable FARS/DFARS restrictions apply to government use.

CPT is a registered trademark of the American Medical Association.

The LOINC® codes, LOINC® table (regardless of format), LOINC® Release Notes, LOINC® Changes File, and LOINC® Users Guide are copyright© 1995-2012, Regenstrief Institute, Inc., and the Logical Observation Identifiers Names and Codes (LOINC) Committee. All rights reserved.

NCQA Notice of Use. Broad public use and dissemination of these measures is encouraged and the measure developers have agreed with NQF that noncommercial uses do not require the consent of the measure developer. Use by health care providers in connection with their own practices is not commercial use. Commercial use of a measure does require the prior written consent of the measure developer. As used herein, a • commercial use• refers to any sale, license, or distribution of a measure for commercial gain, or incorporation of a measure into any product or service that is sold, licensed, or distributed for commercial gain (even if there is no actual charge for inclusion of the measure).

These performance measures were developed and are owned by the National Committee for Quality Assurance (• NCQA•). These performance measures are not clinical guidelines and do not establish a standard of medical care. NCQA makes no representations, warranties, or endorsement about the quality of any organization or physician that uses or reports performance measures and NCQA has no liability to anyone who relies on such measures. NCQA holds a copyright

in this measure and can rescind or alter this measure at any time. Users of the measure shall not have the right to alter, enhance, or otherwise modify the measure and shall not disassemble, recompile, or reverse engineer the source code or object code relating to the measure. Anyone desiring to use or reproduce the measure without modification for a noncommercial purpose may do so without obtaining any approval from NCQA. All commercial uses must be approved by NCQA and are subject to a license at the discretion of NCQA.

© 2009-2012 National Committee for Quality Assurance. All rights reserved.

RED BOOK™ is a trademark of Truven Health Analytics Inc.
